Table 2 Duration of treatment, overall hospital survival and survival by week of ECMO termination
| Â | Â | Â | Â | Overall survival (95% confidence interval) | Survival at weeks 1, 2 and 3 | ||
|---|---|---|---|---|---|---|---|
Clinical category | Number | Median duration (h) | IQR | Â | Week 1 | Week 2 | Week 3+ |
Medical: non-cardiac | 115 | 87 | 31–170 | 49.6% (40.6–58.6) | 53.5% (43.0–63.7) | 42.8% (24.5–63.5) | 25.0% (7.1–59.1) |
Medical: other cardiac disease | 383 | 96 | 48–162 | 38.4% (33.6–43.3) | 37.0% (31.7–42.7) | 42.0% (31.1–53.8) | 47.1% (26.2–69.0) |
Medical: structural heart disease | 296 | 117 | 58–192 | 44.3% (38.7–50.0) | 43.1% (36.4–50.0) | 50.7% (39.3–62.0) | 34.8% (18.8–55.1) |
Medical: myocarditis | 87 | 154 | 96–230 | 64.4% (53.9–73.6) | 70.6% (57.0–81.3) | 62.5% (42.7–78.8) | 41.7% (19.3–68.0) |
Medical: coronary artery disease | 424 | 109 | 51–177 | 40.1% (36.0–45.3) | 40.6% (35.3–46.2) | 42.2% (32.1–52.9) | 35.5% (21.1–53.1) |
Surgical: post VAD | 117 | 68 | 33–122 | 41.9% (33.3–50.9) | 41.0% (32.0–50.5) | 44.4% (18.9–73.3) | 66.7% (20.8–93.9) |
Surgical: post heart transplantation | 175 | 108 | 66–173 | 57.1% (49.7–64.2) | 60.0% (51.4–68.0) | 52.9% (36.7–68.6) | 36.3% (15.2–64.6) |
Surgical: other cardiac | 972 | 87 | 41–146 | 35.9% (33.0–39.0) | 38.7% (35.3–42.1) | 25.3% (19.0–33.0) | 20.0% (10.5–34.8) |
Overall | 2699 | 96 | 47–164 | 41.4% (39.5–43.3) | 42.5% (40.4–44.7) | 39.2% (34.9–43.6) | 32.9% (26.0–40.6) |